New biomarker may guide best use of KRAS inhibitors in lung cancer

by

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib.

Leave A Comment

Your email address will not be published. Required fields are marked *